ArticleAdvanced healthcare materials2026
Smartphone-Enabled Point-of-Care Biosensing Platform With Self-Calibration for Rapid Matrix-Resistant Detection of Multiple AMI Biomarkers in Whole Blood.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute myocardial infarction (AMI) requires rapid diagnosis beyond conventional methods, which suffer from biological interference and complexity, limiting point-of-care (POC) application. To tackle these issues, we have devised an anthraquinone (AQ)-calibrated sensor unit coupled with smartphone-based analysis for universal detection of AMI biomarkers in untreated whole blood. Our novel dual-channel biosensing platform integrates AQ as an intrinsic reference standard, establishing a self-correction mechanism to effectively counteract hematological matrix influences. The platform enables swift quantification at pg/mL levels within 5 min without sample preprocessing, achieving detection limits of 0.3, 19.7, and 0.7 pg/mL for cTnI, Mb, and CK‑MB, respectively. The smartphone‑based intelligent analyzer automates real-time signal processing, creating a closed-loop POC diagnostic setup that shows promise for future at‑home AMI risk monitoring. This technological breakthrough showcases notable resilience to biological matrix interference while upholding analytical sensitivity comparable to clinical standards, representing a significant step toward decentralized cardiovascular emergency management.
Indexed as
Identifiers
42396944What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.